Skip to main content
Clinical Trials/EUCTR2017-001416-11-ES
EUCTR2017-001416-11-ES
Active, not recruiting
Phase 1

Assessment of macular thickness after non-traumatic cataract surgery associated to intracamerular injection of Cefuroxima prepared at the hospital vs Prokam.

Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)0 sites622 target enrollmentAugust 10, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
Enrollment
622
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 10, 2017
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults patients of both genres aged between 18 and 99 years.
  • Patients with cataracts 2 or 3 graded,by the Established in the
  • classification of LOCS III.
  • Patients who have signed inform consent indicating that they have
  • been informed regarding all
  • the clinical trial aspects, or in the event that the subjects of the trial are
  • incapacitated, signature of consent by the family member or legally
  • designated representative.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • A. preoperative:
  • \-Alergia or hypersensitivity to ß\-lactámic antibiotic or to any of the
  • excipients of the clinical trial drugs.
  • \-Pacientes with no proliferative diabetic retinopathy, moderate or
  • severe diabetic macular edema or diabetic retinopathy proliferation
  • (any grade).
  • \- History of uveitis, macular degeneration associate in the Middle (AMD)
  • type of exudative or atrophic, diabetic retinopathy, vein occlusion or
  • central retinal vein branch, epiretinal membrane (SEM) and retinitis
  • pigmentosa.

Outcomes

Primary Outcomes

Not specified

Similar Trials